Format

Send to

Choose Destination
Neurodegener Dis Manag. 2016 Dec;6(6s):9-12.

Evolution of multiple sclerosis spasticity-associated symptoms: latest data.

Author information

1
Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany.

Abstract

In addition to muscle stiffness and increasing mobility restrictions, symptoms commonly associated with multiple sclerosis (MS) spasticity are spasms, sleep disturbances, pain, fatigue and bladder dysfunction. Treatment options include trigger factor avoidance, physiotherapy and antispasticity medication. Oral antispasticity agents commonly used in Germany are baclofen, tizanidine and gabapentin, but physician and patient satisfaction with their effectiveness is low. Over the past few years, randomized controlled trials, observational studies and registry data have demonstrated the positive risk:benefit profile of add-on 9-delta-tetra-hydrocannabinol:cannabidiol oromucosal spray for moderate-to-severe resistant MS spasticity. Herein, evidence for this novel therapeutic option is reviewed. A case study illustrates the level of improvement in daily functioning that is possible in treatment responders.

KEYWORDS:

antispasticity drugs; clinical trials; multiple sclerosis; observational studies; registry studies; spasticity-associated symptoms

PMID:
27874495
DOI:
10.2217/nmt-2016-0047
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center